Lokon Pharma Announces Collaboration to Combine its TME Gene Engineering Product with Anti-PD-1 Antibody Tislelizumab in Pancreatic Cancer
Lokon Pharma continues to develop TME gene engineering product for pancreatic cancer in combination with PD-1 antibody therapy.